MS MBA - PaxMedica, Common Ex Chairman
| PXMDDelisted Stock | USD 0.86 0.18 17.31% |
Insider
MS MBA is Ex Chairman of PaxMedica, Common Stock
| Age | 51 |
| Phone | 914 987 2876 |
| Web | https://www.paxmedica.com |
PaxMedica, Common Management Efficiency
The company has return on total asset (ROA) of (2.5596) % which means that it has lost $2.5596 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.4696) %, meaning that it created substantial loss on money invested by shareholders. PaxMedica, Common's management efficiency ratios could be used to measure how well PaxMedica, Common manages its routine affairs as well as how well it operates its assets and liabilities.PaxMedica, Common Stock currently holds 173.54 K in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Debt can assist PaxMedica, Common until it has trouble settling it off, either with new capital or with free cash flow. So, PaxMedica, Common's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PaxMedica, Common Stock sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PaxMedica, to invest in growth at high rates of return. When we think about PaxMedica, Common's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| James JD | Allarity Therapeutics | 55 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Brian Strem | Kiora Pharmaceuticals | 44 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Nandan BS | Immix Biopharma | 62 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Sharon McBrayer | Palisade Bio | N/A | |
| JD MBA | Immix Biopharma | N/A | |
| Joan Brown | Allarity Therapeutics | 70 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Steen Knudsen | Allarity Therapeutics | 63 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| Robert McRae | Palisade Bio | N/A | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| Chester III | Revelation Biosciences | 44 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
Management Performance
| Return On Equity | -10.47 | ||||
| Return On Asset | -2.56 |
PaxMedica, Common Stock Leadership Team
Elected by the shareholders, the PaxMedica, Common's board of directors comprises two types of representatives: PaxMedica, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PaxMedica,. The board's role is to monitor PaxMedica, Common's management team and ensure that shareholders' interests are well served. PaxMedica, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PaxMedica, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Howard Weisman, CEO Director | ||
| MS MBA, Ex Chairman | ||
| Zachary Rome, COO Director | ||
| Stephen Sheldon, Chief Officer | ||
| David MD, Chief Officer |
PaxMedica, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PaxMedica, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.47 | ||||
| Return On Asset | -2.56 | ||||
| Current Valuation | 388.33 K | ||||
| Shares Outstanding | 7.47 M | ||||
| Shares Owned By Insiders | 8.14 % | ||||
| Shares Owned By Institutions | 1.60 % | ||||
| Number Of Shares Shorted | 637.72 K | ||||
| Price To Earning | 1.90 X | ||||
| Price To Book | 1.83 X | ||||
| EBITDA | (16.15 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in PaxMedica, Pink Sheet
If you are still planning to invest in PaxMedica, Common Stock check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PaxMedica, Common's history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |